Opioids News and Research

RSS

An opioid is a chemical that works by binding to opioid receptors, which are found principally in the central nervous system and the gastrointestinal tract. The receptors in these two organ systems mediate both the beneficial effects and the side effects of opioids.

Lightlake intends to develop a treatment for premenstrual syndrome overeating

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it intends to develop a treatment for premenstrual syndrome (PMS) overeating using its patented technology involving opioid antagonists.

7 Jan 2012

Illegal drug use may be affecting health, death rates worldwide, Lancet report says

"About 200 million people around the world use illegal drugs every year, and that may be taking a toll on health and death rates in various countries, says a report released Thursday in the Lancet," the Los Angeles Times' "Booster Shots" blog reports.

7 Jan 2012

USPTO issues patent to Tris Pharma's OralXR+ platform

Tris Pharma, an emerging specialty pharmaceutical company, announced the US grant of its core technology patent for its OralXR+ platform. This is the first patent grant of a substantial estate filed by Tris Pharma and covers a multitude of actives having modified release formulations comprising drug-ion exchange resin complexes.

7 Jan 2012

ProStrakan announces FDA approval for Transmucosal Immediate Release Fentanyl REMS Access program

ProStrakan, Inc., a subsidiary of Kyowa Hakko Kirin Co. Ltd., and an international specialty pharmaceutical company, today announces that the U.S. Food and Drug Administration has approved the TIRF (Transmucosal Immediate Release Fentanyl) REMS Access program.

31 Dec 2011

Single shared REMS for TIRF products receives FDA approval

The U.S. Food and Drug Administration today approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for the transmucosal immediate-release fentanyl (TIRF) products. This new shared system will replace the individual REMS and allow prescribers and pharmacies to enroll into just one system, easing the burden on the health care system.

30 Dec 2011

Powerful painkiller on its way to the market: Experts worry about addiction woes

Drug makers are on their way to a pure, more powerful version of the nation’s second most-abused medicine, which has addiction experts worried that it could spur a new wave of abuse. The new pills contain the highly addictive painkiller hydrocodone, packing up to 10 times the amount of the drug as existing medications such as Vicodin.

28 Dec 2011

$First study to explore impact of crowding on children with fracture-related pain$

First study to explore impact of crowding on children with fracture-related pain

Crowding in hospital emergency departments has led to a decrease in the timely and effective use of pain medication in children suffering acute long bone fractures, according to a new study by the University of Colorado School of Medicine.

23 Dec 2011

Autism Speaks announces 47 new ASD research grants

Autism Speaks, the world's largest autism science and advocacy organization, today announced the awarding of 47 new research grants totaling $13,242,279 in funding over the next three years.

22 Dec 2011

Actavis enters LOI with QRxPharma to commercialize MoxDuo IR in the U.S.

Actavis Group, the international generic pharmaceuticals company, today announced that its US subsidiary, Actavis Inc, has entered into a binding letter of intent (LOI) with QRxPharma Limited to commercialize MoxDuo IR in the United States.

21 Dec 2011

Diseases of the Colon & Rectum publishes results from Pacira's EXPAREL Phase 3 trial

Pacira Pharmaceuticals, Inc. today announced the publication of data from a placebo-controlled, pivotal Phase 3 trial of EXPAREL (bupivacaine liposome injectable suspension), a non-opioid local analgesic that was recently approved by the U.S. Food and Drug Administration (FDA) for administration into the surgical site to produce postsurgical analgesia.

19 Dec 2011

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

Nektar Therapeutics today announced positive data from a Phase 1 clinical study of NKTR-181 evaluating multiple ascending oral doses of NKTR-181 over an 8-day treatment period in healthy subjects.

14 Dec 2011

Individuals with mood and anxiety disorders may be more likely to abuse opioids

Individuals suffering from mood and anxiety disorders such as bipolar, panic disorder and major depressive disorder may be more likely to abuse opioids, according to a new study led by researchers from the Johns Hopkins Bloomberg School of Public Health. They found that mood and anxiety disorders are highly associated with non-medical prescription opioid use.

14 Dec 2011

Drug users with HIV infection have 74% higher risk of overdose

A study from Rhode Island Hospital is the first to systematically review and analyze the literature on the association between HIV infection and overdose risk.

13 Dec 2011

Study may help personalize pain medication management for sickle cell disease patients

A study that may help personalize pain medication management for sickle cell disease patients is underway at Georgia Health Sciences University.

9 Dec 2011

Medical websites provide harmful information about postherpetic neuralgia treatments

Health information is plentiful on the Internet and many Web surfers consider medical advice they find online to be a cheaper alternative to visiting a doctor, according to some studies. However, the risk of obtaining useless or even harmful medical information from some websites is high for patients with postherpetic neuralgia, a common complication of shingles, according to new research reported in The Journal of Pain, published by the American Pain Society.

1 Dec 2011

Dramatic nationwide rise in opioid use for chronic abdominal pain

Across U.S. outpatient clinics between 1997 and 2008, opioid prescriptions for chronic abdominal pain more than doubled, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

30 Nov 2011

Combination of other opioids with methadone therapy can lead to overdose or fatal consequences

A new study has shown harmful prescription patterns of powerful painkillers among a substantial number of Ontario patients who received methadone therapy to treat their opioid addiction.

29 Nov 2011

Naltrexone for problem gamblers

According to new practice guidelines Australian doctors treating gambling addicts now can consider prescribing an anti-heroin drug, naltrexone, to help problem gamblers control their impulses. Australia has one of the world’s highest rates of problem gamblers, with about 2.1 per cent of Australians experiencing some form of gambling problem.

22 Nov 2011

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

21 Nov 2011

Viewpoints: Questions of partisanship and timing could complicate Supreme Court's decision on health law

The Supreme Court's decision to review the constitutionality of health care reform means it will be issuing a ruling in the middle of the 2012 presidential campaign. This can be a highly politicized court, and, for the public good and its own credibility, it must resist that impulse.

16 Nov 2011

Opioids News and Research

Further Reading

Lightlake intends to develop a treatment for premenstrual syndrome overeating

Illegal drug use may be affecting health, death rates worldwide, Lancet report says

USPTO issues patent to Tris Pharma's OralXR+ platform

ProStrakan announces FDA approval for Transmucosal Immediate Release Fentanyl REMS Access program

Single shared REMS for TIRF products receives FDA approval

Powerful painkiller on its way to the market: Experts worry about addiction woes

First study to explore impact of crowding on children with fracture-related pain

Autism Speaks announces 47 new ASD research grants

Actavis enters LOI with QRxPharma to commercialize MoxDuo IR in the U.S.

Diseases of the Colon & Rectum publishes results from Pacira's EXPAREL Phase 3 trial

Positive data from Nektar's NKTR-181 Phase 1 clinical study for chronic pain

Individuals with mood and anxiety disorders may be more likely to abuse opioids

Drug users with HIV infection have 74% higher risk of overdose

Study may help personalize pain medication management for sickle cell disease patients

Medical websites provide harmful information about postherpetic neuralgia treatments

Dramatic nationwide rise in opioid use for chronic abdominal pain

Combination of other opioids with methadone therapy can lead to overdose or fatal consequences

Naltrexone for problem gamblers

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Viewpoints: Questions of partisanship and timing could complicate Supreme Court's decision on health law

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News